HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $8 Price Target

Benzinga · 07/16 11:58
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral and maintains $8 price target.